Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)

Dewdney, AliceCunningham, DavidTabernero, JosepCapdevila, JaumeGlimelius, BengtCervantes, AndresTait, DianaBrown, GinaWotherspoon, AndrewGonzalez de Castro, DavidChua, Yu Jo2015-12-100732-183Xhttp://hdl.handle.net/1885/51318Keywords: B Raf kinase; capecitabine; cetuximab; K ras protein; oxaliplatin; antineoplastic agent; capecitabine; cetuximab; deoxycytidine; drug derivative; fluorouracil; monoclonal antibody; oxaliplatin; platinum complex; adjuvant chemotherapy; adult; aged; articleMulticenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)201210.1200/JCO.2011.39.60362016-06-14